SCHEMBL6811976

SCHEMBL6811976

COc1cc(Nc2ncc3ccc(=O)n(C)c3n2)cc(OC)c1OC

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTK2 Q05397 19/20 0.64
JAK2 O60674 2/20 0.64
AURKA O14965 1/20 0.64
DAPK3 O43293 1/20 0.64
PAK4 O96013 1/20 0.64
ABL1 P00519 1/20 0.64
NTRK1 P04629 1/20 0.64
LCK P06239 1/20 0.64
FYN P06241 1/20 0.64
CSF1R P07333 1/20 0.64
RET P07949 1/20 0.64
IGF1R P08069 1/20 0.64
MET P08581 1/20 0.64
PDGFRB P09619 1/20 0.64
FGFR1 P11362 1/20 0.64
PDGFRA P16234 1/20 0.64
PRKACA P17612 1/20 0.64
FLT1 P17948 1/20 0.64
LTK P29376 1/20 0.64
KDR P35968 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6808359 0.88 CDK4 (0.74) PTK2JAK2AURKADAPK3PAK4
SCHEMBL6807120 0.85 CDK4 (0.67) PTK2JAK2AURKADAPK3PAK4
SCHEMBL6808118 0.85 CDK4 (0.66) PTK2JAK2AURKADAPK3PAK4
SCHEMBL6809040 0.85 CDK4 (0.80) PTK2FGFR1CDK4CCND1CCND2
SCHEMBL6807735 0.84 CDK4 (0.69) PTK2JAK2AURKADAPK3PAK4
SCHEMBL6808526 0.82 CDK4 (0.70) PTK2JAK2AURKADAPK3PAK4
SCHEMBL6808266 0.82 CDK4 (0.58) PTK2JAK2AURKADAPK3PAK4
SCHEMBL6812324 0.81 CDK4 (0.61) PTK2JAK2AURKADAPK3PAK4
SCHEMBL12529156 0.79 PTK2 (0.78) PTK2JAK2AURKADAPK3PAK4
SCHEMBL5263704 0.78 CDK4 (1.00) FGFR1CDK4CCND1CCND2CCND3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040224958-A1 Pyridopyrimidinone derivatives for treatment of neurodegenerative disease BOOTH RICHARD JOHN (US) 2004-11-11 US claimed
US-20040224958-A1 Pyridopyrimidinone derivatives for treatment of neurodegenerative disease BOOTH RICHARD JOHN (US) 2004-11-11 US disclosed
EP-1255755-A1 PYRIDOPYRIMIDINONE DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE DISEASE WARNER-LAMBERT COMPANY (US) 2002-11-13 EP disclosed
WO-2001055148-A1 PYRIDOPYRIMIDINONE DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE DISEASE WARNER-LAMBERT COMPANY (US) 2001-08-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040224958-A1 Pyridopyrimidinone derivatives for treatment of neurodegenerative disease CDK4, CDKL1, CCNT1 PTK2 131/4885JAK2 849/4885AURKA 145/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.